Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
QURE
#2145
uniQure N.V.
15.6
3
-9.76%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-9.76%
Monthly Change
-34.90%
6 month change
-1.01%
Year Change
+33.02%
Previous Close
17.3
2
Open
15.6
3
Bid
Ask
Low
15.6
3
High
15.6
3
Volume
137
Markets
US Stock Market
Healthcare
QURE
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
uniQure N.V
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.
News
uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know (NASDAQ:QURE)
uniQure earnings in focus as AMT-130 regulatory path looms
Stifel comments on uniQure shares after FDA commissioner remarks
Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug
Applied Materials, Broadcom among market cap stock movers on Thursday
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
UniQure stock tumbles on FDA comments about gene therapy trial
uniQure stock initiated at Peerperform by Wolfe Research
uniQure investors face April 13 deadline for class action lawsuit
Diamond Hill International Strategy Q4 2025 Portfolio Review
uniqure investor lawsuit deadline set for April 13 following FDA setback
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results